What is the safety profile of Kytril in pediatric patients?
Although neither the tablet nor oral solution have been studied in pediatric patients, clinical trials of the intravenous formulation indicate that granisetron is well tolerated by children 2 through 16 years of age receiving chemotherapy. In children less than 2 years of age receiving chemotherapy, the safety and efficacy of Kytril has not been evaluated. Kytril has not been evaluated in children receiving radiation therapy.
